MX2023012245A - Compuestos, composiciones y metodos para el tratamiento del cancer. - Google Patents
Compuestos, composiciones y metodos para el tratamiento del cancer.Info
- Publication number
- MX2023012245A MX2023012245A MX2023012245A MX2023012245A MX2023012245A MX 2023012245 A MX2023012245 A MX 2023012245A MX 2023012245 A MX2023012245 A MX 2023012245A MX 2023012245 A MX2023012245 A MX 2023012245A MX 2023012245 A MX2023012245 A MX 2023012245A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- methods
- compositions
- treating cancer
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163175974P | 2021-04-16 | 2021-04-16 | |
| US202163281493P | 2021-11-19 | 2021-11-19 | |
| PCT/US2022/025083 WO2022221704A1 (en) | 2021-04-16 | 2022-04-15 | Compounds, compositions and methods of treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012245A true MX2023012245A (es) | 2024-03-11 |
Family
ID=81580947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012245A MX2023012245A (es) | 2021-04-16 | 2022-04-15 | Compuestos, composiciones y metodos para el tratamiento del cancer. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240228482A1 (https=) |
| EP (1) | EP4323358A1 (https=) |
| JP (1) | JP2024514339A (https=) |
| KR (1) | KR20240037184A (https=) |
| AU (1) | AU2022256514A1 (https=) |
| BR (1) | BR112023021068A2 (https=) |
| CA (1) | CA3215395A1 (https=) |
| CL (1) | CL2023003068A1 (https=) |
| CO (1) | CO2023015484A2 (https=) |
| IL (1) | IL307732A (https=) |
| MX (1) | MX2023012245A (https=) |
| PE (1) | PE20240767A1 (https=) |
| TW (1) | TW202309023A (https=) |
| WO (1) | WO2022221704A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4359381A4 (en) * | 2021-06-21 | 2025-04-30 | Nimbus Clio, Inc. | Cbl-b modulators and uses thereof |
| US20250042896A1 (en) * | 2021-10-29 | 2025-02-06 | Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | Polycyclic compound as cbl-b inhibitor |
| AU2022379959A1 (en) | 2021-11-05 | 2024-05-09 | Genentech, Inc. | Lactams as cbl-b inhibitors selective over c-cbl |
| WO2023205180A1 (en) | 2022-04-19 | 2023-10-26 | Nurix Therapeutics, Inc. | Biomarkers for cbl, and compositions and methods for their use |
| US20230414598A1 (en) | 2022-06-22 | 2023-12-28 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds and antiemetic agents |
| EP4554586A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer |
| EP4554570A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent |
| AU2023307165A1 (en) * | 2022-07-12 | 2025-02-06 | Hotspot Therapeutics, Inc. | Methods of preparation of heterocyclic compounds |
| WO2024015863A1 (en) * | 2022-07-12 | 2024-01-18 | Hotspot Therapeutics, Inc. | Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation |
| CA3261875A1 (en) * | 2022-07-12 | 2024-01-18 | Hotspot Therapeutics, Inc. | SOLID FORMS OF A TRIAZINE DERIVATIVE AS A CBL-B MODULATOR |
| EP4558504A1 (en) * | 2022-07-18 | 2025-05-28 | Insilico Medicine IP Limited | Cbl-b inhibitors and methods of uses thereof |
| WO2024077236A1 (en) * | 2022-10-07 | 2024-04-11 | Hotspot Therapeutics, Inc. | Compounds, compositions and methods of treating disorders |
| WO2024077244A1 (en) * | 2022-10-07 | 2024-04-11 | Hotspot Therapeutics, Inc. | Compounds, compositions and methods of treating disorders |
| WO2024086730A1 (en) * | 2022-10-19 | 2024-04-25 | Hotspot Therapeutics, Inc. | Heterocyclic cbl-b inhibitors for the treatment of cancer |
| WO2024105563A1 (en) | 2022-11-16 | 2024-05-23 | Pfizer Inc. | Substituted bicyclic pyridone derivatives |
| WO2024131939A1 (en) * | 2022-12-23 | 2024-06-27 | Insilico Medicine Ip Limited | Cbl-b inhibitors and methods of uses thereof |
| EP4653436A1 (en) * | 2023-01-19 | 2025-11-26 | Guangzhou Yufan Nantu Biotechnologies Co., Ltd | Heterocyclic compounds, preparation method therefor and use thereof |
| CN120530105A (zh) * | 2023-01-20 | 2025-08-22 | 海南先声再明医药股份有限公司 | 取代的三环化合物及其应用 |
| WO2024227436A1 (en) * | 2023-05-04 | 2024-11-07 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| WO2025067342A1 (zh) * | 2023-09-27 | 2025-04-03 | 北京望实智慧科技有限公司 | 用作Cbl-b抑制剂的化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3740837A1 (de) * | 1987-11-27 | 1989-06-08 | Schering Ag | Substituierte bicyclische triazole, verfahren zu ihrer herstellung und ihre verwendung als herbizide mittel |
| MY150032A (en) * | 2007-07-19 | 2013-11-29 | Merck Sharp & Dohme | Heterocyclic amide compounds as protein kinase inhibitors |
| AU2008317353B2 (en) * | 2007-10-24 | 2014-08-07 | Merck Sharp & Dohme Llc | Heterocycle phenyl amide T-type calcium channel antagonists |
| CA3041650A1 (en) * | 2016-10-27 | 2018-05-03 | Bayer Aktiengesellschaft | 4,5-annulated 1,2,4-triazolones |
| WO2019131575A1 (ja) * | 2017-12-26 | 2019-07-04 | 住友化学株式会社 | 複素環化合物及びそれを含有する有害節足動物防除剤 |
| CA3136348A1 (en) * | 2019-04-09 | 2020-10-15 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| MX2021015675A (es) * | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| JP2020169215A (ja) * | 2020-07-15 | 2020-10-15 | 住友化学株式会社 | 複素環化合物を用いる有害節足動物防除方法 |
| EP4554570A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent |
| AU2023307165A1 (en) * | 2022-07-12 | 2025-02-06 | Hotspot Therapeutics, Inc. | Methods of preparation of heterocyclic compounds |
| CA3261875A1 (en) * | 2022-07-12 | 2024-01-18 | Hotspot Therapeutics, Inc. | SOLID FORMS OF A TRIAZINE DERIVATIVE AS A CBL-B MODULATOR |
| EP4554586A1 (en) * | 2022-07-12 | 2025-05-21 | Hotspot Therapeutics, Inc. | Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer |
| WO2024015863A1 (en) * | 2022-07-12 | 2024-01-18 | Hotspot Therapeutics, Inc. | Cbl-b inhibitor, compositions comprising a cbl-b inhibitor in a method of treating a disease associated with cell proliferation |
-
2022
- 2022-04-15 AU AU2022256514A patent/AU2022256514A1/en active Pending
- 2022-04-15 EP EP22721591.0A patent/EP4323358A1/en active Pending
- 2022-04-15 IL IL307732A patent/IL307732A/en unknown
- 2022-04-15 TW TW111114558A patent/TW202309023A/zh unknown
- 2022-04-15 CA CA3215395A patent/CA3215395A1/en active Pending
- 2022-04-15 JP JP2023564025A patent/JP2024514339A/ja active Pending
- 2022-04-15 MX MX2023012245A patent/MX2023012245A/es unknown
- 2022-04-15 KR KR1020237039416A patent/KR20240037184A/ko active Pending
- 2022-04-15 BR BR112023021068A patent/BR112023021068A2/pt unknown
- 2022-04-15 PE PE2023002860A patent/PE20240767A1/es unknown
- 2022-04-15 US US18/286,966 patent/US20240228482A1/en active Pending
- 2022-04-15 WO PCT/US2022/025083 patent/WO2022221704A1/en not_active Ceased
-
2023
- 2023-10-13 CL CL2023003068A patent/CL2023003068A1/es unknown
- 2023-11-16 CO CONC2023/0015484A patent/CO2023015484A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022256514A1 (en) | 2023-10-19 |
| KR20240037184A (ko) | 2024-03-21 |
| WO2022221704A1 (en) | 2022-10-20 |
| CO2023015484A2 (es) | 2023-11-30 |
| JP2024514339A (ja) | 2024-04-01 |
| TW202309023A (zh) | 2023-03-01 |
| CL2023003068A1 (es) | 2024-05-03 |
| EP4323358A1 (en) | 2024-02-21 |
| BR112023021068A2 (pt) | 2024-01-23 |
| PE20240767A1 (es) | 2024-04-17 |
| US20240228482A1 (en) | 2024-07-11 |
| IL307732A (en) | 2023-12-01 |
| CA3215395A1 (en) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023012245A (es) | Compuestos, composiciones y metodos para el tratamiento del cancer. | |
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| WO2020160193A3 (en) | Compounds and uses thereof | |
| MX2024005228A (es) | Inhibidores de la sustitución de glicina a cisteína en la posición 12 (g12c) en el homólogo del oncogén viral de sarcoma de rata kirsten (kras). | |
| NZ784224A (en) | Parp1 inhibitors | |
| MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| PH12022551524A1 (en) | Irak degraders and uses thereof | |
| MX2021012216A (es) | Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos. | |
| JOP20210060A1 (ar) | معدلات لمضاد تريبسين ألفا-1 | |
| CA3173629A1 (en) | Braf degraders | |
| PH12022551522A1 (en) | Smarca degraders and uses thereof | |
| MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
| MX2023013173A (es) | Degradadores de cinasa 2 dependiente de ciclina (cdk2) y sus usos. | |
| MY208545A (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | |
| MX2023003973A (es) | Degradadores de transductores de señales y activadores de la transcripción (stat) y usos de los mismos. | |
| EP4643950A3 (en) | Methods for treating testicular and ovarian adrenal rest tumors | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| WO2020055643A3 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
| MX2024004993A (es) | Agentes degradantes de la proteina tirosina cinasa 2 (tyk2) y usos de los mismos. | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
| WO2020021480A3 (en) | Compositions and methods for treating the eye | |
| WO2019143883A3 (en) | Compositions and methods for the treatment of cancer | |
| MX2020012990A (es) | Formulaciones de tegavivint y compuestos relacionados. | |
| WO2022020353A3 (en) | Methods and compositions for treatment and prevention of coronavirus infection | |
| MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. |